Compare Riot Platforms Inc (RIOT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Riot Platforms Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Riot Platforms Inc trades at $22 (market cap $8.35B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 16.1× Riot Platforms Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Riot Platforms Inc nearer its low. Which is the better fit depends on your goals.
| RIOT | VRTX | |
|---|---|---|
Market Cap | $8.35B | $134.06B |
Sector | Technology | Health |
52-Week High | $28.67 | $557.96 |
52-Week Low | $11.83 | $376.62 |
Enterprise Value | $8.76B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RIOT Platforms trades at $22.26, up 2.11% today, with a bullish technical signal from moving averages. The stock shows strong analyst support with 94.7% buy ratings and a $33 consensus price target. Recent news highlights a transformative $9.1 billion AI data center deal with Anthropic, shifting focus from Bitcoin mining to high-margin AI infrastructure. However, fundamental challenges persist with negative net income margins and consecutive earnings misses.
The outlook balances significant AI-driven growth potential against current profitability concerns. The Anthropic partnership provides long-term revenue visibility but execution risks remain. With the stock trading near analyst price targets, upside depends on successful AI transition and improved financial performance. Key risks include competitive pressures, regulatory uncertainty, and continued cash flow challenges.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
